Shares Of Omeros Rocket Higher As Wedbush Lifts Target, Sees Near Tripling In Stock Price
Omeros (NASDAQ: OMER) shares spiked over the $11 technical level in morning trade Wednesday following a mid-day research note from Wedbush's Liana Moussatos. The stock is now up more than 16 percent for the session.
Moussatos boosted her fair value estimate on Omeros from $28 to $32 while reiterating an Outperform rating.
The Wedbush analyst said, "With U.S. and EU regulators formally accepting OMS302 for review, the time clock for approval begins. With a July 2013 submission and our anticipation of a 10-month U.S. review for the OMS302 NDA, we estimate a PDUFA date in May 2014."
Moussatos does not expect any delays given the recent "stellar" results from each Phase 3 trial of OMS302.
Moussatos is modeling for peak global gross sales for the product at around $500 million. She is anticipating a possible partnership and Phase 2 results for OMS824 by the end of 2013.
With Omeros shares last trading at $11.27, Moussatos new fair value estimate suggests potential upside of more than 180 percent.
Latest Ratings for OMER
|Aug 2015||Roth Capital||Initiates Coverage on||Buy|
|Feb 2014||McNicoll Lewis Vlak||Maintains||Buy|
|Apr 2013||WBB Securities||Maintains||Strong Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.